S939
Clinical - Non-malignant & functional radiotherapy
ESTRO 2026
patients (19.44%) experienced side effects: 8 patients (11.11%) grade 1 erythema, 4 patients (5.56%) temporary inflammation and 2 patients (2.78%) initial transitory worsening of pain. Conclusion: Photon radiotherapy at 30 Gy is an effective, non- invasive and well-tolerated alternative for painful plantar fibromatosis, including patients who failed other treatments. It offers high rates of local disease control and symptom relief with a favorable adverse event profile among the patients included in the study. References: de Haan A, van Nes JGH, Kolff MW, van der Toorn PP, Westenberg AH, van der Vegt AE, Groen H, Overbosch J, van der Laan HP, Werker PMN, Langendijk JA, Steenbakkers RJHM. Radiotherapy for Ledderhose disease: Results of the LedRad-study, a prospective multicentre randomised double-blind phase 3 trial. Radiother Oncol. 2023 Aug;185:109718. de Haan A, van Nes JGH, Werker PMN, Langendijk JA, Steenbakkers RJHM. Radiotherapy for patients with Ledderhose disease: Long-term effects, side effects and patient-rated outcome. Radiother Oncol. 2022 Mar;168:83-88. Mozena JD, Hansen EK, Jones PC. Radiotherapy for Plantar Fibromas (Ledderhose Disease). J Am Podiatr Med Assoc. 2022 Mar 16;112(1):19-008. Keywords: Non-malignant, Plantar fibromatosis, Radiotherapy Stereotactic arrythmia radioablation for refractory ventricular tachycardia : long-term outcomes from the Lille experience Camil Hadjar 1 , Cédric Klein 1 , François Brigadeau 1 , Charlotte Potelle 1 , Maxime Noeuvéglise 2 , Erwann Rault 2 , Thomas Lacornerie 2 , Benjamin Longere 3 , Francois Pontana 3 , Didier Klug 1 , Xavier Mirabel 2 , Sandro Ninni 1 1 Cardiology, Institut Coeur Poumon, Lille, France. 2 Radiotherapy, Oscar Lambret Center, Lille, France. 3 Radiology, Institut Coeur Poumon, Lille, France Digital Poster 514 Purpose/Objective: Stereotactic arrhythmia radioablation (STAR) is an emerging treatment that has been reported as an efficient and safe option for selected patients presenting drug-refractory or otherwise intractable ventricular tachycardia (VT) [1]. The aim of this study was to asses long-term efficacy and side effects of
Digital Poster 227
Photon Radiotherapy for Ledderhose disease: Efficacy and Safety in Pain Control and Quality of Life María C. Matienzo Barreto, Lidia Gómez Perea, José J. Martín Ortega, Elena García Morales, Claudio Fuentes Sánchez Radiation Oncology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain Purpose/Objective: Plantar fibromatosis (Ledderhose disease) is a benign soft tissue neoplasm of the plantar aponeurosis that can cause significant pain and walking difficulties. Treatment options range from conservative therapies to surgical excision, which carries a high recurrence rate oscillating between 25% and 100%. Radiotherapy has emerged as an attractive therapeutic alternative option, mainly with superficial or electron radiation therapy. The aim of this study is to report the efficacy and safety of photon radiotherapy with a linear accelerator (LINAC) as a treatment modality for plantar fibromatosis. Material/Methods: A retrospective observational study was conducted on 72 patients with painful plantar fibromatosis, among whom 9 had bilateral fibromatosis (81 treatments administered), treated at a Level 3 hospital's Radiation Oncology Department between 2024 and 2025. All patients received a total dose of 30 Gy delivered in 3 Gy fractions, using 6 MV photons and 3D planning techniques. Treatment response was evaluated through patient-reported questionnaires and clinical visits after 1, 3 and 6 months of treatment, focusing on pain relief using the Visual Analog Scale (VAS) and the impact on daily activities. Results: Minimum follow-up of 3 months (mean follow-up 13.26 months). Median age 52 years old (range 18 – 76), with 75% of the cohort being female. 43 patients (59.72%) had refractory pain that had not responded to conventional treatments. Pain limited daily life for 38 patients (52.78%) prior to treatment, with 9 patients (12.5%) being sedentary or on sick leave and 29 patients (40.28%) having a moderate reduction in their activity. 8 patients (11.11%) continued with limitations due to pain after treatment. A substantial reduction in pain was observed, with the median VAS score improving from 7 before treatment to 3 after treatment. This symptomatic relief correlated with an improvement in their daily activities, reported by 88.89% of patients at six months. 49 patients (68.06%) reported complete resolution of pain, 15 patients (20.83%) experienced partial improvement, and 8 patients (11.11%) showed no response. No growth of the lesions was observed during this time. Only 14
STAR in refractory VT. Material/Methods:
This monocentric retrospective study included all patients who underwent STAR in for refractory VT despite optimal medical therapy and catheter ablation,
Made with FlippingBook - Share PDF online